Cantor Fitzgerald Forecasts Increased Earnings for Omeros

Omeros Co. (NASDAQ:OMER - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Omeros in a report issued on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of ($2.04) per share for the year, up from their prior estimate of ($2.19). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

OMER has been the subject of a number of other research reports. D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of Omeros from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, May 16th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Trading Down 1.9%

Shares of OMER stock traded down $0.06 on Wednesday, hitting $3.16. 569,591 shares of the stock were exchanged, compared to its average volume of 667,872. The business has a 50-day moving average of $6.55 and a 200 day moving average of $8.13. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The firm has a market capitalization of $185.15 million, a P/E ratio of -1.37 and a beta of 2.42.

Institutional Investors Weigh In On Omeros

Large investors have recently added to or reduced their stakes in the business. Truvestments Capital LLC boosted its position in Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC lifted its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Omeros in the fourth quarter valued at about $46,000. Picton Mahoney Asset Management grew its position in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after acquiring an additional 4,404 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Omeros by 14,486.3% during the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,388 shares in the last quarter. Institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.